The oxidative metabolism of dimemorfan by human cytochrome p450 enzymes

Journal of Pharmaceutical Sciences

Volumn 99, Issue 2, 2010, Pages 1063-1077

  Chou, Yueh Ching ^a,b,c   Chung, Yu Ting ^b   Liu, Tsung Yun ^a,b   Wang, Szu Yu ^a   Chau, Gar Yang ^a   Chi, Chin Wen ^a,b   Souček, Pavel ^d   Krausz, Kristopher W ^e   Gelboin, Harry V ^e   Lee, Chen Hsen ^a,b   Ueng, Yune Fang ^b,c,f  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d NATIONAL INSTITUTE OF PUBLIC HEALTH   (Czech Republic)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f NATIONAL RESEARCH INSTITUTE OF CHINESE MEDICINE   (Taiwan)

Author keywords

CYP enzymes; Dimemorfan; Inhibition; Kinetics; Metabolism; Microsomes

Indexed keywords

4 METHYLPYRAZOLE; 6 HYDROXYCHLORZOXAZONE; ALPHA NAPHTHOFLAVONE; CHLORZOXAZONE; CYTOCHROME P450; CYTOCHROME P450 2B6; CYTOCHROME P450 2C19; CYTOCHROME P450 2C9; CYTOCHROME P450 2D6; CYTOCHROME P450 3A4; DEXTROMETHORPHAN; DEXTRORPHAN; DIMEMORFAN PHOSPHATE; KETOCONAZOLE; MONOCLONAL ANTIBODY; NIFEDIPINE; O DEMETHYLASE; PAROXETINE; SULFAPHENAZOLE; TRANYLCYPROMINE;

ADULT; AEROBIC METABOLISM; AGED; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG METABOLISM; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; KINETICS; LIQUID CHROMATOGRAPHY; LIVER MICROSOME; MALE; MASS SPECTROMETRY;

EID: 74049101611     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21866     Document Type: Article

References (34)

1. Ida H. 1997. The nonnarcotic antitussive drug dimemorfan: A review. Clin Ther 19:215-231.
2. Chou YC, Ueng YF, Chou CY, Tien JH. 2005. Dimemorfan N-demethylation by mouse liver microsomal cytochrome P450 enzymes. Life Sci 77:735-745.
3. Nassar AEF, Adams PE. 2003. Metabolite characterization in drug discovery utilizing robotic liquidhandling, quadruple time-of-flight mass spectrometry and in-silico prediction. Curr Drug Metab 4: 259-271.
4. Guengerich FP. 1995. Human cytochrome P450 enzymes. In: Ortiz de Montellano PR, editor. Cytochrome P450. New York: Plenum Press. p 473-535.
5. Yamaori S, Yamazaki H, Suzuki A, Yamada A, Tani H, Kamidate T, Fujita K, Kamataki T. 2003. Effects of cytochrome b5 on drug oxidation activities of human cytochrome P450 (CYP) 3As: Similarity of CYP3A5 with CYP3A4 but not CYP3A7. Biochem Pharmacol 66:2333-2340.
6. Wrighton SA, Stevens JC. 1992. The human hepatic cytochrome P450 involved in drug metabolism. Crit Rev Toxicol 22:1-21.
7. Shimada T, Yamazaki H, Mimura M, Inui Y, Guengerich FP. 1994. Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: Studies with liver microsomes of 30 Japanese and Caucasians. J Pharmacol Exp Ther 270:414-423.
8. Lasker JM, Wester MR, Aramsombatdee E, Raucy JL. 1998. Characterization of CYP2C19 and CYP2C9 from human liver: Respective roles in microsomal tolbutamide, S-mephenytoin, and ormeprazole hydroxylations. Arch Biochem Biophys 353:16-28.
9. Yamazaki H, Inoue K, Shaw PM, Checovich WJ, Guengerich FP, Shimada T. 1997. Different contributions of cytochrome P450 2C19 and 3A4 in the oxidation of omeprazole by human liver microsomes: Effects of contents of these two forms in individual human samples. J Pharmacol Exp Ther 283:434-442.
10. Guengerich FP. 1994. Preparation of microsomal and cytosolic fractions. In: Hayes AW, editor. Principles and methods of toxicology. 3rd edition. New York: Raven Press. p 1267-1268.
11. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
12. Parikh A, Gillam EMJ, Guengerich FP. 1997. Drug metabolism by Escherichia coli expressing human cytochrome P450. Nat Biotechnol 15:784-788.
13. Omura T, Sato R. 1964. The carbon monooxidebinding pigment of liver microsomes. I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2378.
14. Pohl RJ, Fouts JR. 1980. A rapid method for assaying the metabolism of 7-ethoxyresorufin by microsomal subcellular fractions. Anal Biochem 107:150-155.
15. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T, Waxman DV. 1986. Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
16. Peter R, Böcker R, Beaune PH, Iwasaki M, Guengerich FP, Yang CS. 1990. Hydroxylation of chlorzoxazone as a specific probe for human liver microsomal P450 IIE1. Chem Res Toxicol 3:566-573.
17. Yamazaki H, Inoue K, Shimada T. 1998. Roles of two allelic variants (Arg144Cys and Ile359Leu) of cytochrome P450 2C9 in the oxidation of tolbutamide and warfarin by human liver microsomes. Xenobiotica 28:103-115.
18. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, Trager WF. 1997. Mechanism-based inactivation of human liver microsome P450 2A6 by 8-methoxysoralen. Drug Metab Dispos 25:1407-1415.
19. Kimura M, Yamazaki H, Fujieda M, Kiyotani K, Honda G, Saruwatari J, Nakagawa K, Ishizaki T, Tamataki T. 2005. CYP2A6 is a principle enzyme involved in hydroxylation of 1,7-dimethylxanthine, a main caffeine metabolite, in human. Drug Metab Dispos 33:1361-1366.
20. SalsaliM,Holt A, Baker GB. 2004. Inhibitory effects of themonoamine oxidase inhibitor tranylcypromine on cytochrome P450 enzymes CYP2C19, CYP2C9, and CYP2D6. Cell Mol Neurobiol 24:63-75.
21. Härtter S, Tybring G, Friedberg T, Weigmann H, Hiemke C. 2002. The N-demethylation of the doxepin isomers is mainly catalyzed by the polymorphic CYP2C19. Pharm Res 19:1034-1037.
22. Bertelsen KM, Venkatarishnan K, von Moltke LL, Obach RS, Greenblatt DJ. 2003. Apparent mechanism-based inhibition of human CYP2D6 in vitro by paroxetine: Comparison with fluoxetine and quinidine. Drug Metab Dispos 31:289-293.
23. Newton DJ, Wang RW, Lu AYH. 1995. Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154-158.
24. Galetin A, Clarke SE, Houston JB. 2002. Quinidine and haloperidol as modifiers of CYP3A4 Activity: Multisite kinetic model approach. Drug Metab Dispos 30:1512-1522.
25. Lin Y, Lu P, Tang C, Mei Q, Sandig G, Rodrigues AD, Rushmore TH, Shou M. 2001. Substrate inhibition kinetics for cytochrome P450-catalyzed reactions. Drug Metab Dispos 29:368-374.
26. Gelboin HV, Krausz K. 2006. Monoclonal antibodies and multifunctional cytochrome P450: Drug metabolism as paradigm. J Clin Pharmacol 46:353-372.
27. Houston JB, Kenworthy KE. 2000. In vitro-in vivo scaling of CYP kinetic data not consistent with the classical Michaelis-Menten model. Drug Metab Dispos 28:246-254.
28. Wang JS, DeVane CL. 2003. Involvement of CYP3A4, CYP2C8, and CYP2D6 in the metabolism of (R)- and (S)-methadone in vitro. Drug Metab Dispos 31:742-747.
29. Yamazaki H, Ueng YF, Shimada T, Guengerich FP. 1995. Roles of divalent metal ions in oxidations catalyzed by recombinant cytochrome P450 3A4 and replacement of NADPH-cytochrome P450 reductase with other flavoproteins, ferredoxin, and oxygen surrogates. Biochemistry 34:8380-8389.
30. Fogelman SM, Schmider J, Venkatakrishnan K, von Moltke LL, Harmatz JS, Shader RI, Greenblatt DJ. 1999. O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: Effect of metabolic inhibitors and SSRI antidepressants. Neuropsychopharmacology 20:480-490.
31. Yu A, Dong H, Lang D, Haining RL. 2001. Characterization of dextromethorphan O- and N-demethylation catalyzed by highly purified recombinant human CYP2D6. Drug Metab Dispos 29:1362-1365.
32. Niwa T, Okada K, Hiroi T, Imaoka S, Narimatsu S, Funae Y. 2008. Effect of psychotropic drugs on the 21-hydroxylation of neurosteroids, progesterone and allopregnanolone, catalyzed by rat CYP2D4 and human CYP2D6 in the brain. Biol Pharm Bull 31:348-351.
33. Aklillu E, Persson I, Bertilsson L, Johansson I, Rodrigues F, Ingelman-Sundberg M. 1996. Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles. J Pharmacol Exp Ther 278:441-446.
34. Goldstein DB, Need AC, Singh R, Sisodiya SM. 2007. Potential genetic causes of heterogeneity of treatment effects. Am J Med 120:S21-S25.